先日の精子研究会でもお配り致しましたが下記の内容をUPします
Stockholm Male Reproductive Health Statement 2018 12/5/2018
We, scientists, public health professionals and clinicians working in spermatology, are calling on governments, organizations, the scientific and medical communities, and individuals to acknowledge the importance of male reproductive health for the survival of the human and other species, to increase efforts and resources allocated to studying the causes of disruption of male reproductive health, and to implement policies to remove hazards to, and promote optimal environments for, male health and reproduction.
Fertility, both female and male, and reproductive function in general are essential for the health and survival of our species. Now there is growing evidence of the effect of the male’s age and health on the offspring, that testis function is an important marker of a man's health, and that his semen quality is a strong indicator of his future health.
Given that the sperm cell has unique qualities and a highly specific biological function, the field of spermatology continues to be a significant resource for enhancing our understanding of the most fundamental biological processes and the impact of the environment on the formation of life itself. This has potential broad implications for humans and humanity.
Until now, the field of male reproduction research has been surprisingly neglected, possibly due to cultural biases, wrongly considering reproduction to be mainly a female issue. In addition, the successful and widespread introduction of assisted reproductive technologies to circumvent even severe male factor infertility has lessened motivation to sustain research in this field as these technologies are considered to be the “remedy” for almost all causes of male infertility. However, we currently know very little about any possible long-term consequences, and so it is critical to continue research to further improve these clinical technologies and not succumb to short-cutting strategies
A recent meta-analysis reported a steep decline in human sperm counts over the last 40 years. This decline is a source of great concern, particularly when considered alongside reports of other adverse male reproductive health trends in human and animal populations, and specific studies on hazards to male reproductive development and function.
Against this background we call on:
Governments and organizations to: acknowledge decreased male fertility as a major public health problem and to recognize the importance of male reproductive health for the survival of the human and other species; increase efforts and resources allocated to studying the causes of disruption of male reproduction; introduce reproductive health surveillance systems; and implement policies to prevent exposure to hazards to male fertility and ensure optimal environments for male reproductive health. Proper health promotion and education programs aimed at improving the reproductive health of populations and individuals, with specific emphasis on recognizing the crucial contribution of both sexes, are critical. There also needs to be strengthened regulatory requirements regarding the effect of pharmaceuticals on sperm function.
The scientific and medical community to work together to develop a global and local research agenda targeted at understanding the causes and implications of disruption of male reproductive health, and to encourage interdisciplinary research, taking one health approach and considering the developmental origin of health and diseases. We should train scientists and clinicians at all levels in andrology and in recognizing the crucial contribution of both sexes to reproduction.
Individuals (public) to understand that male reproductive health is critical for fecundity, that it can be evaluated, and that each man’s environment and life choices can affect his sperm quantity, quality and function, which can reflect his future health. Raising awareness may enable men to make preventive life choices and request adequate medical assessment as a part of infertility investigation.
Dr. Hagai Levine MD, MPH
Head, Environmental Health Track, School of Public Health
Hebrew University-Hadassah, Jerusalem, Israel Professor (Emeritus) Hideo Mohri PhD, University of Tokyo and National Institute for Basic Biology, Japan Professor Anders Ekbom MD, PhD, Karolinska Institute Department of Medicine, Solna, Sweden
Professor Joël Drevet PhD, GReD Laboratory INSERM U1103 - CNRS UMR6293, Faculty de Medicine, CRBC.
Université Clermont Auvergne (UCA), Clermont-Ferrand, France Dr. Liliana Ramos PhD, Senior Clinical Embryologist, Head IVF-Laboratory, Radboud University Medical Centre, Department of Gynaecology and Reproduction, Nijmegen, Netherlands Professor (Emeritus) Geoff Parker PhD, University of Liverpool, Liverpool, UK
Professor Eduardo Roldan PhD, Reproductive Ecology and Biology Group, Department of Biodiversity and Evolutionary Biology, Museo Nacional de Ciencias Naturales (CSIC), Madrid, Spain Professor Luca Jovine PhD,
Karolinska Institute, Department of Biosciences and Nutrition & Center for Innovative Medicine Huddinge, Sweden Professor Sabine Koelle DVM, Anatomy & Developmental Biology, School of Medicine, Health Science Centre, University College Dublin, Belfield, Dublin, Ireland
Associate Professor Anna Lindstrand MD, PhD, Clinical Genetics, Department of Molecular Medicine and Surgery
Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden Associate Professor Simone Immler PhD, School of Biological Sciences, University of East Anglia, Norwich Research Park, UK Dr. Sharon Mortimer PhD
Director, Oozoa Biomedical, Vancouver, Canada
Adjunct Senior Lecturer, University of New South Wales, Australia, President, Fertility Matters Canada
Dr. David Mortimer PhD
President, Oozoa Biomedical, Vancouver, Canada, Honorary Senior Lecturer, University of Dundee, Scotland, UK Professor Gerhard van der Horst MD, PhD, Physiology Medical School and Department of Animal Science, Stellenbosch University, Research Associate, National Zoological Gardens, Pretoria, South Africa Dr. Sumio Ishijima PhD, School of Life Science and Technology, Tokyo Institute of Technology, Japan
Natalie Aneck-Hahn, Director: Environmental Chemical Pollution and Health Research Unit
Deputy Director: Medical Natural Sciences (Urology)
Faculty of Health Sciences, University of Pretoria, South Africa Associate Professor Elisabetta Baldi PhD, Department of Experimental and Clinical Medicine, University of Florence, Italy Professor Emeritus Roelof Menkveld PhD, Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Stellenbosch Universtity, Tygerberg, South Africa
Dr. Susan A Rothman, PhD HCLD, Laboratory Director and President, Fertility Solutions Inc., Cleveland, Ohio, USA Professor Aleksander Giwercman, Dept. of Translational Medicine, Lund University, Malmö, Sweden Professor Yvonne Giwercman, Dept. of Translational Medicine, Lund University, Malmö, Sweden
Dr. Mats Holmberg MD ANOVA - Andrology, Sexual Medicine, and Transmedicine, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Associate Professor Ulrik Kvist MD,PhD, ANOVA - Andrology, Sexual Medicine, and Transmedicine, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden Dr. Lars Björndahl MD, PhD, ANOVA - Andrology, Sexual Medicine, and Transmedicine, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Associate Professor Stefan Arver MD, PhD, Director of ANOVA - Andrology, Sexual Medicine, and Transmedicine, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Dr. Rebecka Holmberg PhD,
ANOVA - Andrology, Sexual Medicine, and Transmedicine, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Associate Professor John Flanagan PhD, ANOVA - Andrology, Sexual Medicine, and Transmedicine, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
